Liquidia Co. (NASDAQ:LQDA) Insider Sells $31,785.00 in Stock

Liquidia Co. (NASDAQ:LQDA) insider Rajeev Saggar sold 2,445 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $13.00, for a total value of $31,785.00. Following the transaction, the insider now owns 267,943 shares in the company, valued at $3,483,259. This represents a 0.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Rajeev Saggar also recently made the following trade(s):

• On Tuesday, January 14th, Rajeev Saggar sold 6,249 shares of Liquidia stock. The stock was sold at an average price of $11.78, for a total value of $73,613.22.

Liquidia Trading Down 0.3 %

Shares of LQDA stock opened at $14.36 on Friday. The firm’s 50 day moving average is $11.65 and its 200-day moving average is $11.10. Liquidia Co. has a 1 year low of $8.26 and a 1 year high of $16.99.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Scotiabank initiated coverage on Liquidia in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $19.00 target price on shares of Liquidia in a research report on Thursday, January 9th. Wells Fargo & Company initiated coverage on shares of Liquidia in a report on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price on the stock. Lifesci Capital initiated coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Liquidia in a research note on Thursday, November 14th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Liquidia has an average rating of “Buy” and an average target price of $25.38.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Signaturefd LLC lifted its stake in shares of Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after acquiring an additional 9,984 shares during the period. Clear Harbor Asset Management LLC acquired a new position in Liquidia during the 3rd quarter valued at about $100,000. Ballentine Partners LLC acquired a new position in Liquidia in the third quarter valued at approximately $110,000. Whitcomb & Hess Inc. boosted its position in shares of Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after purchasing an additional 1,074 shares during the last quarter. Finally, Walleye Trading LLC boosted its holdings in Liquidia by 54.7% during the third quarter. Walleye Trading LLC now owns 13,201 shares of the company’s stock worth $132,000 after buying an additional 4,670 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).